Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3,Double-blinded, Double Dummy, Positive Drug, Parallel, Randomised Controlled Multicenter Trial to Evaluate Efficacy and Safety of Anaprazole Compared With Rabeprazole in Patients With Duodenal Ulcers

Next Previous
Trial Profile

A Phase 3,Double-blinded, Double Dummy, Positive Drug, Parallel, Randomised Controlled Multicenter Trial to Evaluate Efficacy and Safety of Anaprazole Compared With Rabeprazole in Patients With Duodenal Ulcers

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 10 Jul 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Anaprazole (Primary) ; Rabeprazole
  • Indications Duodenal ulcer
  • Focus Registrational; Therapeutic Use
  • Sponsors Sihuan Pharmaceutical Holdings Group

Most Recent Events

  • 14 Feb 2020 According to an Sihuan Pharmaceutical Holdings Group media release, this study will be conducted in about 30 to 45 clinical centres across the PRC. The Study achieved significant progress with the first subject being enrolled in January 2020 after its launch.
  • 14 Feb 2020 Status changed from not yet recruiting to recruiting, according to an Sihuan Pharmaceutical Holdings Group media release.
  • 04 Feb 2019 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top